Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
about
Therapeutic options in peripheral T cell lymphomaPurine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignanciesHighly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic ReviewT-cell lymphomas, a challenging disease: types, treatments, and future.Bendamustine salvage therapy for T cell neoplasms.Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter studyGemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.Toward a Biology-Driven Treatment Strategy for Peripheral T-cell LymphomaBFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHDSuspension of accrual in phase II cancer clinical trials.Prediction of desmoid tumor progression using miRNA expression profilingHow I treat the peripheral T-cell lymphomasStrategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve.Peripheral T-cell lymphomas: a review of current approaches and hopes for the future.Romidepsin for peripheral T-cell lymphoma.Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.Bendamustine: role and evidence in lymphoma therapy, an overview.From empiric to mechanism-based therapy for peripheral T cell lymphoma.Emerging drugs for T-cell lymphoma.Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.X. Challenges and future directions in peripheral T-cell lymphoma.The role of alisertib in treatment of peripheral T-cell lymphomas.Investigational drugs for T-cell lymphoma.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateHow I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine.Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma.Recent advances in understanding and managing T-cell lymphoma.Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine.Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma.Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma
P2860
Q26748857-FD8D1BEC-5849-408C-94A6-A8D9C881DA44Q28540830-5D4CF112-0C04-44D1-BDC4-5378F5860A48Q28554530-D5285201-8F21-4B6F-9309-518C1D06AB3CQ30244553-C8CD5F87-E085-4850-91CE-D8FDCF8A2D8FQ33407099-CD57F0BB-12F8-4C14-AF5E-DBC1557627B8Q33410756-843FED09-F15C-487C-899E-34AF4CAA19F6Q33434137-6FBAEB53-38E1-4473-B1BD-88CAC174CF4DQ33436867-8157CDB8-58BE-47E9-9690-D4A05A8AC304Q33670421-AF4C798B-9813-4362-BA44-5BBD67414DA1Q34660110-FD03273F-C9A3-4A6D-9851-72102D9386F9Q35164526-0A99082D-4D9E-4596-A86B-559E205D75CCQ35674236-E9474124-588C-4E87-A34F-FD90B17D6450Q35865090-947C33DD-D07F-4E44-B026-1F3EA230C55AQ37391571-3B43DD5A-048A-4F30-9E05-4892DB3231C7Q38113568-8E1B6340-3B0E-4C23-A9E3-D7550CD8212CQ38132813-5E8E359D-8EBF-4C6D-8141-7E712122A860Q38152510-FEB89930-CE06-4254-A64E-A1FC0DEDA857Q38158084-48E51946-8ABA-491E-813A-E0F3780A221EQ38186617-B8A001F3-4FF6-4F6E-9CCD-0E1B637E5611Q38196943-966411DD-20A0-445C-82EB-5CDADC81DBA6Q38206120-7831E2E4-44F8-487C-8381-448B0B5E6522Q38260926-FD87FBBE-D1F5-4EAA-85B5-24C0F5C33F2CQ38524000-9B4B2727-7BFE-40E5-AE22-6DE180F1050AQ38581916-98081DE3-622D-4711-A8C2-202EB475EFE2Q38635909-3ADF26D3-1417-4500-B097-1F21B6407E46Q38642648-C0312CAF-E719-4FA6-89C0-A132B3DF96CFQ38782072-327ADDA9-B4ED-497D-9D6E-6818B86C22D3Q39005626-B785AE28-339C-493C-B030-6F1B0E71D269Q41362824-35810BE5-2920-496B-B687-832EA26919B4Q45072628-5B4838FB-9118-4E31-90C4-CA11629D9CD3Q47131247-E691CA7F-B56D-4A8B-A3CF-F4A760F27FEAQ50889557-AF1F2423-06B9-45CA-AE37-5A2492145301Q53060890-1B3DD896-7E0B-487D-8FD7-44653C1EAFF1Q57494289-D90295D5-A14E-4F55-BF0C-2BF7925C6F54
P2860
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Results from a prospective, op ...... l lymphomas: the BENTLY trial.
@ast
Results from a prospective, op ...... l lymphomas: the BENTLY trial.
@en
type
label
Results from a prospective, op ...... l lymphomas: the BENTLY trial.
@ast
Results from a prospective, op ...... l lymphomas: the BENTLY trial.
@en
prefLabel
Results from a prospective, op ...... l lymphomas: the BENTLY trial.
@ast
Results from a prospective, op ...... l lymphomas: the BENTLY trial.
@en
P2093
P50
P356
P1476
Results from a prospective, op ...... l lymphomas: the BENTLY trial.
@en
P2093
Alain Saad
Aline Schmidt-Tanguy
Anne Banos
Antoine Martin
Bachra Choufi
Bertrand Joly
Gandhi Damaj
Jean-Marc Schiano-de Collela
Jean-Pierre Marolleau
Jean-Pierre Vilque
P304
P356
10.1200/JCO.2012.43.7285
P407
P577
2012-10-29T00:00:00Z